You're both completely right, but remember that government
You're both completely right, but remember that government agencies don't give a crap whether or not their positions on a subject make any sense, only that their asses are covered.
Until they have indisputable clinical proof from fully accredited government facilities, they don't care if 99% of the most prestigious research centers in the world are singing the praises of how good something is for you.
How much CBD a person gets from normal doses of THC from MJ usage is known to be much lower than high doses of high quality CBD supplements.
While there is a tremendous amount of research that has been and still is being done on the ingestion of CBD and the fantastic health benefits revealed from it, government agencies are still not about to approve the use of more concentrated, higher doses.
They need the CYA confirmation of fully government accredited labs signing off on it as being low or no risk, even if not immediately pursuing the testing so far as to determine long or even short term health benefits which is much more costly to do.
They don't take it that far with supplements, even most vitamins. I take one called Trans-Resveratrol with added polyphenols. Very prestigious but independent research has determined it to be one of the most potent antioxidants ever discovered and isolated and extremely beneficial to one's overall immune health, but on the label is the old CYA statement: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease".
Well, it's been determined by many of the best research groups in the world to be one of the best disease preventing supplements you can take, but it could be quite a wait to get the FDA's stamp of approval. They simply won't hurry to subsidize clinical research on most of those non-patentable preventative supplements because there's not much capital pushing for it like there are with patentable drugs.
CBD is definitely not in the same boat with most non-patentable supplements. We're talking billions hanging on full CBD approval, so it should be no surprise that the research is already underway in those government accredited laboratories. It won't be long and the green lights will be shining bright in the U.S. and Canada.
8
Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trailblazing Change in the Golf World It's like watching a high-stakes game of chess where pieces are worth billions. White Knight Capital Corp. has thrown its hat into the ring with the Public Investment Fund of Saudi Arabia to overhaul LIV Golf Enterprises. This isn't your average Monday morning golf chat; it's full-on corporate drama with financial steroids. Debt Swap...
Continue Reading
A New Era for Offshore Wind Operations Mark my words, folks, this launch ain't just some minor milestone swaying gently on the industry seas. ZPMC's 'Wind of Ocean' is about to kickstart a whole new game in Europe's offshore wind space. Built with brains and brawn, this vessel embodies the future of sustainable and efficient offshore operations. The announcement from...
Continue Reading
Breaking Down MiniTool MovieMaker 8.9's Revamp Kicking off the day with some noteworthy news in the creative software arena, MiniTool's latest update to its MovieMaker program is grabbing attention. It’s not often you hear software developers hitting the right balance between functionality and simplicity as they've done with this release. Keyframe Animation: The Star of...
Continue Reading
Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...
Continue Reading
Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...
Continue Reading
Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...
Continue Reading
FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...
Continue Reading
Challenges in Identity Governance Emerge for 2026 Imagine a world where digital identities run wild—unmonitored, orphaned, dormant. Welcome to 2026, where identity governance and administration (IGA) face a reckoning, dragging enterprises into the spotlight as they scramble to protect against identity chaos. With Pathlock’s recent recognition in the Gartner Market...
Continue Reading
Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...
Continue Reading
A Diplomatic Balancing Act Xi Jinping's recent diplomatic tour, climaxing at the Shanghai Cooperation Organization (SCO) Summit and extending through critical visits to Kyrgyzstan and Egypt, paints a compelling picture of China's strategic intentions. For those of us watching the geopolitical chessboard, it's like seeing a master strategist at work—pondering a tricky...
Continue Reading
Top 5 Most Recently Viewed Articles
Theravance and Zymeworks: What's the Deal? First things first, the numbers. Theravance Biopharma, the biotech entity waving its NASDAQ: TBPH ticker, is about to jump into bed with Zymeworks, another player in the pharma game. The pitch? One hundred seventy-six bucks a share in cold, hard cash, plus a contingent value right. That's right—sweet on paper, but always worth...
Continue Reading
Stock splits surged back into the limelight recently, flipping the script on a strategy that had been gathering dust. Once thought outdated, these moves have become hot again, reflecting how companies with robust performances can maintain investor interest while managing share prices effectively. When you see a stock split, it’s often more than just a number game; it's...
Continue Reading
Roc Nation Collaborates with Musicow for Music Equity Innovation Roc Nation has embarked on an exciting partnership with Musicow, a South Korean fintech firm. This collaboration aims to introduce the first Music Equity Service Provider (MESP) in the United States. By allowing music rights holders to buy, sell, and trade shares in music royalty revenue, this initiative...
Continue Reading
Insights from Recent FDA Activities The U.S. Food and Drug Administration (FDA) has released an overview of recent important developments aimed at enhancing public health and safety. These updates offer invaluable information about various health issues, product approvals, and guidance to manufacturers. Investigation of E. coli Outbreak Recently, the FDA updated its...
Continue Reading
Understanding Insider Transactions at BorgWarner Recently, a notable insider sale captured attention. Isabelle McKenzie, the Vice President of BorgWarner, made headlines when she sold 2,500 shares, totaling around $100,025. This transaction was officially reported in a filing to the SEC, particularly through a Form 4. Such insider activities often spark curiosity among...
Continue Reading